DSS Document Security Systems Inc.

DSS Announces its AuthentiGuard as a Service Anti-Counterfeiting App is now Available on The App Store

DSS Announces its AuthentiGuard as a Service Anti-Counterfeiting App is now Available on The App Store

ROCHESTER, N.Y., July 20, 2020 (GLOBE NEWSWIRE) -- Document Security Systems, Inc. (“DSS” or the “Company”) (NYSE American: DSS), a multinational company operating businesses focusing on brand protection technology, blockchain security, direct marketing, healthcare, real estate, and securitized digital assets, is pleased to announce the Company’s new AuthentiGuard as a Service (AGaaS) app is now available on The App Store.

Brands of all shapes and sizes experience counterfeit issues. Those same brands lack the ability to have their packaging engage the consumer, in an economical way. DSS now provides an easy as 1-2-3 solution, with the world’s first syndicated Brand Protection and Consumer Engagement Product.

AGaaS is designed for rapid implementation and empowers the entire supply chain with technology to verify product authenticity. Using the AGaaS platform, manufacturers are provided with a unique high-security multi-layered marking to incorporate in each product, while consumers can download an app via Google Play (coming soon) or The App Store that provides the ability to scan and confirm authenticity of a product, providing a worldwide track and trace solution with real-time reports to track each individual package and flag any counterfeits in the process, as well as the option of adding Augmented Reality marketing messages to improve consumer engagement.

DSS is hosting a webinar for brands interested in learning more about the AGaaS solution. The webinar is ideal for smaller brands as well as printers and packagers seeking new ways to service their customers. Current brand and print customers of DSS will provide insight into their experience with the service and demonstrations of Augmented Reality consumer experiences and authentication systems will be provided.

Event Details:

Topic:"AuthentiGuard as a Service - Authentication as easy as 1-2-3"
 
When:11:00 am ET, Wednesday, July 22, 2020
 
Time:One (1) Hour
 
Hosts:Mike Buell, VP Business Development (DSS)
 
Register:

Still not sure if you should join? to see real life examples and register today!



DSS Digital executives will be available to answer questions at the conclusion of the webinar.



Questions? Contact DSS VP Business Development Mike Buell via email at .

About Document Security Systems, Inc.

DSS is a multinational company operating businesses focused on brand protection technology, blockchain security, direct marketing, healthcare, real estate, and securitized digital assets. Its business model is based on a distribution sharing system in which shareholders will receive shares in its subsidiaries as DSS strategically spins them out into IPOs. Its historic business revolves around counterfeit deterrent and authentication technologies, smart packaging, and consumer product engagement. DSS is led by its Chairman and largest shareholder, Mr. Fai Chan, a highly successful global business veteran of more than 40 years specializing in corporate transformation while managing risk. He has successfully restructured more than 35 corporations with a combined value of $25 billion.

For more information on DSS visit .

Investor Contact:

Dave Gentry, CEO

RedChip Companies Inc.

407-491-4498

Safe Harbor Disclosure

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, statements related to the Company's intended use of proceeds and other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results or events to differ materially from those projected. These risks and uncertainties, many of which are beyond our control, include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of development activities; our ability to attract, integrate and retain key personnel; our need for substantial additional funds; patent and intellectual property matters; competition; as well as other risks described in the section entitled "Risk Factors" in the prospectus and in our other filings with the SEC, including, without limitation, our reports on Forms 8-K and 10-Q, all of which can be obtained on the SEC website at Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations and beliefs. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

EN
20/07/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Document Security Systems Inc.

 PRESS RELEASE

Sentinel Brokers Company, Inc., a Subsidiary of DSS, Inc., Receives FI...

Sentinel Brokers Company, Inc., a Subsidiary of DSS, Inc., Receives FINRA Approval to Act as Underwriter and Selling Group Member for Corporate Securities Offerings NEW YORK, April 24, 2025 (GLOBE NEWSWIRE) -- Sentinel Brokers Company, Inc. (“Sentinel”), a FINRA-registered broker-dealer and a subsidiary of DSS, Inc. (NYSE American: DSS), is pleased to announce that it has received approval from the Financial Industry Regulatory Authority (FINRA) to act as an underwriter and selling group member for corporate securities offerings. This regulatory milestone significantly enhances Sentinel’...

 PRESS RELEASE

DSS, Inc. Announces Sale of Celios® to Impact BioMedical, Streamlining...

DSS, Inc. Announces Sale of Celios® to Impact BioMedical, Streamlining Portfolio for Strategic Growth ROCHESTER, N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company focused on innovation-driven business models, today announced the sale of its Celios® air purification asset to Impact BioMedical Inc. (NYSE American: IBO) in a strategic, all-equity transaction valued at approximately $1.15 million. This divestiture aligns with DSS’ ongoing strategy to optimize its portfolio and concentrate on core growth areas. Celios® is a cutting-edge air purifi...

 PRESS RELEASE

DSS, Inc. Issues Letter to Shareholders

DSS, Inc. Issues Letter to Shareholders NEW YORK, Feb. 03, 2025 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) a multinational company operating businesses within diversified market sectors that strategically acquires and develops assets to increase shareholder value, today issued the following letter to shareholders: Dear Esteemed Shareholders, I am pleased to provide you with significant updates regarding the leadership of DSS, Inc. and to outline the strategic direction we are pursuing as a Company. It is with great honor that I announce my appointment as Interim Chief Executive...

DSS Inc: 1 director

A director at DSS Inc bought 1,025,746 shares at 0.975USD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...

 PRESS RELEASE

DSS, Inc. Celebrates Impact BioMedical Inc.'s Successful IPO and Proud...

DSS, Inc. Celebrates Impact BioMedical Inc.'s Successful IPO and Proudly Advances Shareholder Value NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a dedicated supporter and investor in Impact BioMedical Inc. (NYSE American: IBO), is delighted to announce the successful pricing of Impact BioMedical's initial public offering (IPO). Impact BioMedical, a trailblazer in advancing human healthcare and wellness solutions, has set its IPO price at $3.00 per share, with an initial offering of 1,500,000 shares. Trading under the ticker symbol “IBO,” these shares will b...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch